Intellia Therapeutics is trading at $16.13 (-4.22%) as recent insider selling reports add pressure. - This comes after a significant surge in the stock over the past month, driven by positive Phase 3 lonvo-z results for hereditary angioedema. - The lonvo-z clinical trial demonstrated an 87% reduction in monthly attacks with no serious adverse events, but investors may be booking gains after the strong performance.